Filing Details
- Accession Number:
- 0001209191-19-002289
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-01-04 18:54:29
- Reporting Period:
- 2019-01-02
- Accepted Time:
- 2019-01-04 18:54:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1724605 | Carole Ho | C/O Denali Therapeutics Inc. 151 Oyster Point Boulevard, Second Floor South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-01-02 | 4,875 | $19.43 | 143,515 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2019-01-02 | 900 | $20.24 | 142,615 | No | 4 | S | Indirect | See footnote |
| Common Stock | Acquisiton | 2019-01-03 | 5,775 | $5.28 | 8,552 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-01-03 | 2,777 | $18.90 | 2,777 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-01-04 | 5,950 | $5.28 | 8,727 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-01-04 | 1,500 | $19.30 | 7,227 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-01-04 | 4,450 | $20.03 | 2,777 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-01-03 | 5,775 | $0.00 | 5,775 | $5.28 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-01-04 | 5,950 | $0.00 | 5,950 | $5.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 108,335 | 2026-07-01 | No | 4 | M | Direct | |
| 102,385 | 2026-07-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 46,875 | Direct | |
| Common Stock | 25,000 | Indirect | See footnote |
Footnotes
- The shares are held of record by Carole Ho and Rajat Rohatgi.
- The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.11 to $20.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.13 to $20.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Includes 1,894 shares acquired on May 31, 2018 and 883 shares acquired on November 30, 2018 under the Issuer's 2017 Employee Stock Purchase Plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.56 to $19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.77 to $19.76 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.81 to $20.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter.
Billionaire Hedge Funds
